enEnglisch
PAMSARC
Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Recruiting
Summary
Pasireotide causes growth inhibition by binding to specific receptors, the somatostatin receptors. It is approved for the treatment of Cushing's disease and acromegaly, two conditions caused by tumors in the pituitary gland. The PAMSARC study investigates the drug outside of its originally intended and approved use.
The treatment lasts between 4 and 36 months. As part of the PAMSARC clinical trial, it is planned that all participants will be treated with the investigational drug pasireotide. All patients will receive monthly injections of the active ingredient pasireotide into the gluteal muscles.
The study observes how the treatment affects the time until disease progression, overall survival, and aspects of quality of life in the patients.
Main inclusion criteria
- Age ≥ 13 and ≤ 50 years
- locally advanced or metastatic SySa or DSRCT
- high SSTR2/3/5 mRNA expression, proven by MASTER or INFORM
- no curative treatment option available
- For patients (≥16 years): Karnofsky-Index ≥ 80%
- For patients (<16 years): Lansky-Index36 ≥ 80%
Sponsor
Heidelberg University Hospital